Open Access
| Issue |
BIO Web Conf.
Volume 214, 2026
The 2025 International Conference on Biomedical, Bioinformatics and Statistics (ICBBS 2025)
|
|
|---|---|---|
| Article Number | 01018 | |
| Number of page(s) | 4 | |
| Section | Biomedical, Bioinformatics and Statistics | |
| DOI | https://doi.org/10.1051/bioconf/202621401018 | |
| Published online | 02 February 2026 | |
- X. Liu, J. Deng, R. Zhang, J. Xing, Y. Wu, W. Chen, B. Liang, D. Xing, J. Xu, M. Zhang, The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy. Front. Immunol. 14, 1335252 (2023). [Google Scholar]
- K. Ai, B. Liu, X. Chen, C. Huang, L. Yang, W. Zhang, J. Weng, X. Du, K. Wu, P. Lai, Optimizing CAR-T cell therapy for solid tumors: Current challenges and potential strategies. J. Hematol. Oncol. 17, 105 (2024). [Google Scholar]
- N. Roussot, C. Kaderbhai, F. Ghiringhelli, Targeting immune checkpoint inhibitors for non-small-cell lung cancer: Beyond PD-1/PD-L1 monoclonal antibodies. Cancers 17, 906 (2025). [Google Scholar]
- D.-C. Mo, J.-F. Huang, P. Lin, S.-X. Huang, H.-L. Wang, P.-H. Luo, X.-J. Liang, The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: A meta-analysis. Sci. Rep. 14, 78159 (2024). [Google Scholar]
- P. M. Forde, J. Spicer, S. Lu, M. Provencio, T. Mitsudomi, M. M. Awad, E. Felip, S. R. Broderick, J. R. Brahmer, S. J. Swanson, K. Kerr, C. Wang, T.-E. Ciuleanu, G. B. Saylors, F. Tanaka, H. Ito, K.-N. Chen, M. Liberman, E. E. Vokes, J. M. Taube, Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973–1985 (2022). [Google Scholar]
- L. N. Mathieu, E. Larkins, A. K. Sinha, P. S. Mishra-Kalyani, S. Jafri, G. S. Kalavar, S. Ghosh, K. B. Goldberg, R. Pazdur, J. A. Beaver, H. Singh, FDA approval summary: Atezolizumab as adjuvant treatment following surgical resection and platinum-based chemotherapy for stage II to IIIA NSCLC. Clin. Cancer Res. 29, 2973–2978 (2023). [Google Scholar]
- H. A. Wakelee, M. Liberman, T. Kato, M. Tsuboi, S. Lee, J. He, S. Gao, K.-N. Chen, C. Dooms, M. Majem, E. Eigendorff, G. L. Martinengo, O. Bylicki, D. Rodriguez-Abreu, J. E. Chaft, S. Novello, J. Yang, S. M. Keller, A. Samkari, J. Spicer, KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early-stage NSCLC. J. Clin. Oncol. 41, LBA100 (2023). [Google Scholar]
- S. Keam, N. Turner, F. G. Kugeratski, R. Rico, J. Colunga-Minutti, R. Poojary, S. Alekseev, A. B. Patel, Y. Li, A. Sheshadri, M. E. Loghin, K. Woodman, A. E. Aaroe, S. Hamidi, P. C. Iyer, N. L. Palaskas, Y. Wang, R. Nurieva, Toxicity in the era of immune checkpoint inhibitor therapy. Front. Immunol. 15, 1447021 (2024). [Google Scholar]
- M. Sposito, S. Eccher, I. Scaglione, A. Avancini, A. Rossi, S. Pilotto, L. Belluomini, The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents. Expert Opin. Biol. Ther. 24, (2024). [Google Scholar]
- N. Coleman, T. A. Yap, J. V. Heymach, F. Meric-Bernstam, X. Le, Antibody-drug conjugates in lung cancer: Dawn of a new era? npj Precis. Oncol. 7, 5 (2023). [Google Scholar]
- C. Zanchetta, L. D. Marchi, M. Macerelli, G. Pelizzari, J. Costa, G. Aprile, F. Cortiula, Antibody-drug conjugates in non-small cell lung cancer: State of the art and future perspectives. Int. J. Mol. Sci. 26, 221 (2025). [Google Scholar]
- T. S. K. Mok, S.-M. Lim, I. Okamoto, M. Perol, S. Novello, C. A. Dooms, J.-M. Sun, S. C.-H. Kao, P. A. Jänne, M. Reck, C. E. Steuer, M. Nishio, Y.-L. Lung, X. Li, R. Fougeray, R. Kudchadkar, J. Wu, S. Esker, A. Passaro, Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated advanced NSCLC after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. J. Clin. Oncol. 43, 8506 (2025). [Google Scholar]
- L. Trudu, G. Rovesti, G. Neri, G. Pugliese, M. Silingardi, L. Brini, G. Golinelli, M. C. Baschieri, E. Lallo, G. Guaitoli, F. Bertolini, C. Di Giovane, P. L. Filosso, M. Dominici, C. Chiavelli, CAR-T for lung cancers: Challenges and innovations. Lung Cancer 207, 108711 (2025). [Google Scholar]
- P. S. Adusumilli, M. G. Zauderer, I. Riviere, S. B. Solomon, V. W. Rusch, R. E. O Cearbhaill, A. Zhu, W. Cheema, N. K. Chintala, E. Halton, J. Pineda, R. Perez-Johnston, K. S. Tan, B. Daly, J. A. A. Filho, D. Ngai, E. McGee, A. Vincent, C. Diamonte, J. L. Sauter, A phase I trial of regional mesothelin-targeted CAR T-cell therapy in malignant pleural disease with pembrolizumab. Cancer Discov. 11, 2748–2763 (2021). [Google Scholar]
- N. Tang, C. Cheng, X. Zhang, M. Qiao, N. Li, W. Mu, X.-F. Wei, W. Han, H. Wang, TGF-ß inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, e133977 (2020). [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.